Get the Stockscreener App
30.94
7.92%
2.27
Pre-market:
30.70
-0.24
-0.78%
Cg Oncology Inc stock is traded at $30.94, with a volume of 1.27M.
It is up +7.92% in the last 24 hours and up +18.59% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$28.67
Open:
$28.64
24h Volume:
1.27M
Relative Volume:
1.60
Market Cap:
$2.36B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-24.36
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+15.82%
1M Performance:
+18.59%
6M Performance:
+24.76%
1Y Performance:
-15.21%
1-Day Range:
$28.32
$31.95
1-Week Range:
$26.22
$31.95
52-Week Range:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
30.94 | 2.09B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
Can CG Oncology Inc. withstand a market correctionJuly 2025 Rallies & Fast Moving Stock Trade Plans - khodrobank.com
Chart based exit strategy for CG Oncology Inc.Weekly Loss Report & Verified Momentum Watchlists - Newser
Detecting support and resistance levels for CG Oncology Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - Newser
Song Hong Fang, CG Oncology director, sells $2.78m in shares - Investing.com
CG Oncology Directors Sell Shares, Buy Others Amid Market Volatility. - AInvest
How does CG Oncology Inc. score in quality rankingsWeekly Risk Report & AI Powered Buy/Sell Recommendations - khodrobank.com
Understanding CG Oncology Inc.’s price movementM&A Rumor & Low Volatility Stock Suggestions - Newser
Can CG Oncology Inc. deliver alphaJuly 2025 Levels & Capital Protection Trading Alerts - khodrobank.com
What moving averages say about CG Oncology Inc.July 2025 Final Week & Free Expert Approved Momentum Trade Ideas - Newser
Will CG Oncology Inc. stock go up soonShort Setup & Real-Time Volume Triggers - Newser
Real time breakdown of CG Oncology Inc. stock performance - Newser
CG Oncology Inc. stock chart pattern explained2025 Biggest Moves & Long-Term Investment Growth Plans - Newser
Ani Pharmaceuticals shares rise 1.98% after-hours following CG Oncology's PIVOT-006 study enrollment completion. - AInvest
Will CG Oncology Inc. benefit from macro trendsSwing Trade & Accurate Intraday Trading Signals - Newser
CG Oncology Completes Enrollment for Phase 3 Study - Orange County Business Journal
CG Oncology completes enrollment for bladder cancer therapy trial - Investing.com
CG Oncology completes enrollment in PIVOT-006 - TipRanks
CG Oncology Completes Rapid Enrollment in Phase 3 Study for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Quiver Quantitative
CG Oncology Completes Enrollment in PIVOT-006 Trial for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - AInvest
Largest-Ever Trial: 360 Patients Join CG Oncology's Breakthrough Bladder Cancer Study One Year Early - Stock Titan
Using economic indicators to assess CG Oncology Inc. potentialMarket Activity Recap & Entry Point Confirmation Signals - Newser
Real time alert setup for CG Oncology Inc. performanceJuly 2025 Momentum & Daily Profit Focused Screening - Newser
Developing predictive dashboards with CG Oncology Inc. data2025 Retail Activity & Real-Time Volume Triggers - Newser
What are CG Oncology Inc.’s technical support levels2025 Volatility Report & Risk Managed Trade Strategies - khodrobank.com
How to build a custom watchlist for CG Oncology Inc.Market Movement Recap & Community Supported Trade Ideas - Newser
Analyzing CG Oncology Inc. with risk reward ratio chartsTrade Performance Summary & AI Powered Buy/Sell Recommendations - Newser
Will CG Oncology Inc. outperform the marketWall Street Watch & Intraday High Probability Alerts - Newser
Should you hold or exit CG Oncology Inc. nowEntry Point & Free Verified High Yield Trade Plans - Newser
Published on: 2025-09-03 00:18:12 - Newser
Can CG Oncology Inc. sustain earnings growthWeekly Earnings Recap & Long-Term Safe Investment Plans - khodrobank.com
Is CG Oncology Inc. stock reversal real or fakeBear Alert & Low Risk High Reward Trade Ideas - Newser
Technical signs of recovery in CG Oncology Inc.Quarterly Portfolio Review & Free Low Drawdown Momentum Trade Ideas - Newser
Using flow based indicators on CG Oncology Inc.2025 Price Momentum & Consistent Growth Stock Picks - Newser
Is CG Oncology Inc. still worth holding after the dipQuarterly Performance Summary & Verified Chart Pattern Trade Signals - Newser
Is CG Oncology Inc. a candidate for recovery playJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Visualizing CG Oncology Inc. stock with heatmapsNew Guidance & Smart Money Movement Alerts - Newser
CG Oncology Inc. stock trend forecastForecast Cut & AI Driven Stock Movement Reports - Newser
Can CG Oncology Inc. hit a new high this monthTrade Entry Summary & Low Risk Entry Point Tips - Newser
Chart based analysis of CG Oncology Inc. trendsJuly 2025 Momentum & Risk Managed Investment Entry Signals - Newser
What is the target price for CG Oncology Inc. stockJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - khodrobank.com
Risk adjusted return profile for CG Oncology Inc. analyzedWeekly Loss Report & Reliable Entry Point Trade Alerts - Newser
Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025: Emerging Therapies and Treatment Advances - AInvest
How CG Oncology Inc. stock performs during market volatilityDividend Hike & AI Forecast for Swing Trade Picks - Newser
How cyclical is CG Oncology Inc.’s revenue streamQuarterly Trade Review & Reliable Breakout Stock Forecasts - khodrobank.com
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):